"Nowadays, there are needs to draw up policies for evidence-based scientific technology and innovation, and to construct systems to measure and evaluate them. JST has also began investigations toward achieving the measurement of scientific technology and innovation; and as part of those investigations, by analyzing the state of funding, research papers and patents, JST is seeing influences that return on investment and science have on technology. We selected Scopus Custom Data as the underlying database for our analysis because it provides citation information, a large amount of data, and clear relations between authors and their affiliations," commented Mari Jibu of JST's Research Institute of Science and Technology for Society.
"Attention is being placed on citations in patents as a new index to measure the influence of scientific articles. JST used Scopus data for its analysis on the return on investment of science and technology policies. We are honored to be able to cooperate with JST in this way, and will continue to provide support from now on," added Niels Weertman, Director, Performance & Planning and Collaboration Tools for Elsevier.
About Japan Science and Technology Agency (JST)
Japan Science and Technology Agency (JST) aims to establish Japan as a
nation built on the creativity of science and technology and innovation, as a
core organization for implementing Japan's science and technology policy in
line with the objectives of the Science and Technology Basic Plan. JST's
mission is to promote science and technology in Japan'/>"/>
Copyright©2010 PR Newswire.
All rights reserved
Related biology technology :
1. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
2. Exclusive Rights to Kuvan(TM) Data Licensed to Asubio Pharma in Japan
3. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
6. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
7. NPS Pharmaceuticals Announces Approval of Cinacalcet HCl in Japan
8. Neurocrine Biosciences and Dainippon Sumitomo Pharma (DSP) Announce Agreement to Develop and Commercialize Indiplon in Japan
9. Masimo Corporation Given Approval to Market the Masimo Rad-57 Pulse CO-Oximeter in Japan
10. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
11. American Scientists Named as Laureates of the 2008 (24th) Japan Prize